Slide 1: Orion Half-Year Financial Report January-June 2026
Orion Half-Year Financial Report January-June 2026 17 July 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q2 2026 Highlights
Q2 2026 Highlights • Growth accelerated and profitability improved • Strong growth in Nubeqa® royalties and product sales • Great quarter for Branded Products • Several key milestones reached in the research and development of ODM-212 3 17 July 2026 © Orion Corporation
Slide 4: Q2 2026 Financial highlights
Q2 2026 Financial highlights Net sales, EUR million Operating profit, EUR million Earnings per share, EUR Operating profit margin 33.9% (25.1%) +25.2% +68.8% +69.7% 521.6 176.6 1.00 416.5 104.6 0.59 Q2/2025 Q2/2026 Q2/2025 Q2/2026 Q2/2025 Q2/2026 4 17 July 2026 © Orion Corporation
Slide 5: Net sales bridge (MEUR)
Net sales bridge (MEUR) 521.6 -1.1 -2.9 3.6 0.3 10.3 95.0 416.5 Q2/2025 Innovative Branded Products Generics and Animal Health Fermion Translation Q2/2026 Medicines Consumer Health differences and other operations 5 17 July 2026 © Orion Corporation The figures in the chart are rounded, which is why
Slide 6: Operating profit bridge (MEUR)
Operating profit bridge (MEUR) -0.1 -4.3 -15.2 176.6 76.6 -2.2 104.6 17.3 Q2/2025 Changes in Changes in prices, Royalties Milestones Other operating Fixed costs Q2/2026 sales volume COGS, product income and mix and FX expenses 6 17 July 2026 © Orion Corporation The figures in the chart are rounded,
Slide 7: H1 2026 Financial highlights
H1 2026 Financial highlights Net sales, EUR million Operating profit, EUR million Earnings per share, EUR Operating profit margin 31.0% (23.7%) +21.8% +59.6% +60.2% 939.3 291.3 1.64 771.0 182.5 1.02 H1/2025 H1/2026 H1/2025 H1/2026 H1/2025 H1/2026 7 17 July 2026 © Orion Corporation
Slide 8: Innovative Medicines
Innovative Medicines +60.3% Nubeqa® sales (MEUR) +64.8% 392.0 237 241.6 10.2 4.8 213 64 48 166 244.5 152 145 146.7 140 12.9 48 6.6 36 44 50 NET SALES MEUR NET SALES MEUR 236.8 381.8 95 92 72 26 165 173 38 140.1 231.6 50 21 116 118 18 96 95 69 51 54 32 2024 2024 2024 2024 2025 2025 2025 2025 2026 202
Slide 9: Branded Products
Branded Products • Robust growth momentum in +12.8% +9.9% Women’s Health therapy area, 90.7 172.9 driven by Divina® product range 80.4 14.0 157.4 22.2 7.9 15.0 • Easyhaler® budesonide- formoterol contributed 27.7 51.7 significantly to the growth in the 28.2 51.5 respiratory therapy area NET SALES ME
Slide 10: Generics and Consumer Health
Generics and Consumer Health • Slight decline in generic -0.8% +0.3% prescription drugs net sales and 135.0 133.9 266.7 267.4 slight increase in consumer health 31.1 products net sales 31.9 64.4 66.3 • License agreement with Shilpa to commercialise intravenous (iv) nivolumab biosimilar in Europe NET
Slide 11: Animal Health
Animal Health • Timing of deliveries impacted -7.9% -2.4% 36.8 72.0 negatively Q2 net sales against 70.2 the strong comparison period 33.9 • In May, Tessie® (tasipimidine oral solution) received approval from the U.S. Food and Drug Administration (FDA). NET SALES MEUR NET SALES MEUR • We expect our
Slide 12: Fermion
Fermion • Growth is mostly due to timing of +19.9% +17.1% deliveries and it is expected to 21,5 36,8 level out during H2/2026 17,9 31,4 • Water damage at one Fermion plant in Hanko in July during summer maintenance break • Recovery plan in place and NET SALES MEUR NET SALES MEUR implemented • Based
Slide 13: Top 10 products and net sales split in H1 2026
TOP 10 products and net sales split in H1 2026 EUR vs. Product or product portfolio million 2025 1. Nubeqa® 381.8 +64.9% 4% 7% 2. Easyhaler® product portfolio 95.3 +7.2% 3. Entacapone products1 44.4 -4.0% 4. Divina® series 22.2 +47.6% 42% 5. Dexdomitor®, Domitor®, Domosedan® and Antisedan® 16.9 -12.
Slide 14: Orion Pharma's key clinical development pipeline
Orion Pharma’s key clinical development pipeline Invented by Developer(s) Trial/compound Indication Phase I Phase II Phase III ARASTEP (darolutamide) prostate cancer (BCR2) DASL-HiCaP (darolutamide) (Neo-)adjuvant prostate cancer OMAHA-003 (opevesostat) prostate cancer (later-line mCRPC3) OMAHA-004
Slide 15: Aspirational benefits of ODM-212, a TEAD inhibitor, in patients with cancer
Aspirational benefits of ODM-212, a TEAD inhibitor, in patients with cancer Monotherapy-TEADES Study TEADCO-Combination Study (ODM-212 has anti-tumour activity) (ODM-212 has resistance-prevention activity) Cancers driven by the Hippo pathway Prevention of cancer treatment resistance Targeting solid
Slide 16: Key milestones reached for ODM-212: a potential best-in-class TEAD inhibitor
Key milestones reached for ODM-212: a potential best-in-class TEAD inhibitor OPPORTUNITY Targeting Hippo pathway dysregulated tumours • Small molecule oral pan-TEAD inhibitor • Rare cancers with limited treatment options such as mesothelioma and EHE1 PHASE 1 RESULTS TEADES – Phase 1 results announce
Slide 17: Orion listed among Europe's Climate Leaders 2026 by Financial Times
Orion listed among Europe’s Climate Leaders 2026 by Financial Times Our emissions reductions and roadmap towards our near-term science-based target (combined Scope 1&2) tCO2e 45 000 40 000 We switched to using 100% 2023 is the baseline year Our roadmap carbon-free electricity at our for our science-
Slide 18: Outlook for 2026
Outlook for 2026 (specified on 17 July 2026) Net sales EUR 2,000 million–EUR 2,100 million Operating profit EUR 650 million–EUR 750 million 18 17 July 2026 © Orion Corporation
Slide 19: Upcoming events
Upcoming events Interim Report 1–9/2026 28/10/2026 Financial Statement Release 2026 17/2/2027 AGM planned to be held 23/3/2027 Interim Report 1–3/2027 22/4/2027 Half-Year Financial Report 1–6/2027 20/7/2027 Interim Report 1–9/2027 27/10/2027 19 17 July 2026 © Orion Corporation